Today, I’m excited to share that we’re rolling out the MiniMed 670G system, beginning with those in the Priority Access program. But before we get into details, on behalf of the entire Medtronic team, I want to extend both my gratitude and my commitment to you.
We’re incredibly inspired by the many positive stories from those who’ve experienced the system (like Nicky  and John ) – either in the clinical trial or the initial Customer Training Phase  – and from the anticipation expressed by our community. We are honored and humbled by the opportunity to contribute to a big change in your life with diabetes.
Thank you also for your patience.
We know the rollout of this first-of-its-kind technology is taking time. We’re doing our best to process orders and provide training as quickly as possible. However, the demand for the product surpassed even our own expectations. And we strongly believe that ensuring you have a great experience is more important than speed.
With its exclusive SmartGuard HCL technology, the MiniMed 670G system takes a more active role in diabetes management than any technology that’s come before it. The system automatically adjusts basal insulin delivery throughout the day to maintain stable glucose levels. As a result, we’re seeing people spending more Time in Range and less time thinking about their diabetes, which is fantastic! But that also means it’s more critical than ever that each person who goes on the system and their healthcare team is comfortable. Even if it requires a little more time and patience from both of us.
Our first and foremost commitment to you is that we’ll do everything we can to ensure you have a great experience with this transformational new technology. We’re also committed to communicating with you as clearly as possible throughout the process. We’ve heard your feedback that some earlier information wasn’t as clear as it could have been. If that’s the case, we’re sorry and we’re committed to doing better. We’re here to answer your questions and help however we can.
Now, to answer the big question: “When can I get the MiniMed 670G system?”
Next Steps for Priority Access Program Participants
For those of you enrolled in the Priority Access program, thanks again for your patience. Just as we committed to you when you enrolled in the program, you may be among the first to receive the MiniMed 670G system. Through this special program, you may also upgrade to the MiniMed 670G system for as little as $0, provided you return your MiniMed 630G system and participate in activities such as taking surveys and sharing your experiences. For next steps, look for an email with the subject “Place Your Order For The MiniMed 670G System,” read it carefully and either click the “yes” button to place your order or “no” to decline. The email will explain the simple, 5-step process.
There are a few items I’d like to point out. I’m not sure we’ve been quite clear enough on these in the past, so I want to do my best here.
1. To confirm your order, you will need to pay $299. Because of the way our systems and processes are set up, this is needed to move forward with the order. Our email will direct you to the online store. The $299 will not be charged until your pump ships. It will also be refunded as promptly as possible once you return your MiniMed 630G system and complete the surveys and other activities, bringing your cost down to $0. Update as of 6/16/17: Please see clarification in bold below for how this process will work.
2. Because this technology is different from your current system, we need a new prescription from your doctor to ship your MiniMed 670G system. We’ll work with your doctor to get this.
3. We may also need to contact your insurance company. While your provider will not be paying for your MiniMed 670G pump or transmitter, we may need to verify coverage for your ongoing supplies.
4. We expect Priority Access pump shipments to begin over the next few weeks and continue through Fall 2017.
Next Steps For Those NOT in Priority Access
Because it’s important that we keep our commitment to those who enrolled in Priority Access, we will ship MiniMed 670G pumps and CGM to those people first. This could take a few months. In the meantime:
1. If you are new to pump therapy or ready to upgrade from a previous system, you can get started here .
2. If you are still in-warranty on your current insulin pump and CGM system, we’ll have information about upgrade programs later this summer. Today, you can learn more about the MiniMed 670G system here  and stay up to date be following us on Facebook  and Instagram .
Thank you once again for putting your trust in us. We’re thrilled to bring the diabetes community the world’s first hybrid closed loop system. And we welcome your questions and feedback – whether it’s about this first-of-its-kind product, the rollout, training or service. If you’ve been with us a long time you know that we’re not just here to provide the most advanced technology. Service, support and training are also important parts of how we help you through your journey with diabetes. So ask us your questions. Let us know how we’re doing. And stay connected  with us.
IMPORTANT CLARIFICATION (6/16/17):
Hello everyone, I want to apologize for the confusion and inconvenience around this process and provide some clarification. Through our System Access program, you have the ability to reduce the amount you pay down to $0 when you upgrade to the MiniMed 670G system. To do this, you need to do two things:
1. Return your MiniMed 630G pump and transmitter within 120 days of your MiniMed 670G pump shipment. We will provide you a return envelope.
2. Complete a set of activities that includes taking surveys, sharing your story and uploading to CareLink. These activities must be completed within 120 days from when your MiniMed 670G system is shipped.
Note: Please know that by completing these activities you give us permission to use the content. This helps us better understand you, so we can develop products and services that better meet your needs.
The total value assigned to this set of activities we are asking you to complete is $299. Therefore, if you choose not to do these activities, you will be charged $299 after the 120 day period ends. If you choose to do these activities, this amount will either be refunded or credited promptly after you 1) return your MiniMed 630G system AND 2) complete the activities. Both of these steps must be completed within 120 days from when your MiniMed 670G system is shipped.
You have two options for how to manage the $299 value: a Medtronic account debit or an upfront credit card charge.
Medtronic Account Debit Option
For the debit option, we’ll defer the payment from you and instead create a debit on your Medtronic account. This means our system will show a balance owed of $299, but your credit card will not be charged upfront.
1. If you return your MiniMed 630G pump and transmitter and complete the required activities, you’ll owe $0 and will not be billed.
2. If you choose not to complete the required activities, you’ll be billed the $299 after 120 days.
3. If you choose not to return the MiniMed 630G pump and transmitter, you’ll be billed $3,700 for the full cost of the system.
Upfront Credit Card Charge Option
1. If you pay upfront and return your MiniMed 630G system before beginning the activities, we’ll refund each of the required activities as you complete them, incrementally bringing down the $299 balance.
2. If you return your MiniMed 630G system after you complete the required activities, you’ll receive one refund payment once we receive your pump.
3. You must both return the pump and complete the activities within 120 days from shipment of your MiniMed 670G system in order to receive the refund.
For Those Who Have Already Placed Your Order
If you’ve already placed your order, your credit card has not been charged. When we are ready to ship your order, we’ll reach out to you to review your options. At that time, you can choose either the Medtronic Account Debit Option or Upfront Credit Card Charge Option. No action is needed at this time.
Thank you very much for your patience.
Important Safety Information
The Medtronic MiniMed 670G system requires a prescription and is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of Type 1 diabetes mellitus in persons, fourteen years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed 670G System includes SmartGuard technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values.
The Guardian Sensor (3) is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a finger stick may be required. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not on values provided by the Guardian Sensor (3).
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Do not use the serter on products other than the Enlite sensor or Guardian Sensor (3). Medtronic cannot guarantee the safety or efficacy of this product if used with other products. The reservoir is contraindicated for the infusion of blood or blood products. Infusion sets are indicated for subcutaneous use only and not for intravenous (IV) infusion or the infusion of blood or blood products. Insulin pump therapy is not recommended for those who are unwilling to perform at least four blood glucose tests per day. As insulin pumps use rapid acting insulin only, BG testing is required to help identify rapid glycemic deterioration due to insulin infusion occlusion, infusion site problems, insulin stability issues, user error, or a combination of these. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional.
The safety of the 670G system has not been studied in people with impaired kidney function. Please let your healthcare professional know if you have kidney disease so you and your healthcare professional can determine if the potential benefits of using the system outweigh the risks. The safety of the 670G system has not been studied in pregnant women, people with type 2 diabetes, or in people using other anti-hyperglycemic therapies apart from insulin. Please let your healthcare professional know if any of these conditions apply to you so you and your healthcare professional can determine if the potential benefits of using the system outweigh the risks.
For complete safety information, please consult the appropriate User Guide.
*The CONTOUR®NEXT LINK 2.4 Meter is used with the MiniMed 630G system. The CONTOUR®NEXT LINK Meter is used with the MiniMed 530G system.